Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19 may worsen radiation side effects in breast cancer patients

NCT ID NCT07188116

Knowledge-focused Sponsor: Zhejiang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study examines whether having COVID-19 increases the chance of lung inflammation (radiation pneumonitis) in breast cancer patients receiving radiation therapy. Researchers will review medical records of 200 patients to compare outcomes between those who had COVID-19 and those who did not. The goal is to understand if COVID-19 adds extra risk, which could help guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study finds a link, it could help doctors better manage radiation therapy for breast cancer patients who have had COVID-19.
What could go wrong
This is a small, single-center retrospective study, so results may not apply to everyone. It only looks at past records, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Breast cancer patients who underwent radiotherapy at the Cancer Center of Zhejiang Hospital between January 1, 2021, and June 30, 2024, were screened for eligibility.

Ages

18 to 80 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. patients with pathologically or cytologically confirmed primary breast cancer, 2. aged 18 years or older but younger than 80 years, 3. with complete and reliable medical records, 4. for those with COVID-19 infection, documented evidence of a positive test result. Exclusion Criteria: 1. concomitant pulmonary malignancies, 2. a history of prior thoracic radiotherapy, 3. concurrent pulmonary infections other than COVID-19 during radiotherapy, 4. missing key data with loss to follow-up, 5. or any other condition considered unsuitable for enrollment by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm COVID-19 radiation pneumonitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer COVID -19 Radiation pneumonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhejiang Hospital, Department of Oncology, Hangzhou, China, 310030

    Hangzhou, Zhejiang, 310030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.